News 02.07.2018 Schlieren (Zurich), Switzerland, July 2, 2018 – Kuros Biosciences (SIX: KURN) announced today it recorded the first commercial use last week of MagnetOs in the U.S., and the company expects to ramp up its commercial activities in Europe and the U.S. in the second half of 2018. Joshua M. Ammerman, M.D....
External events
Event date: 15.09.2018
To enhance the interactions between academia, industry, and society by bringing together all relevant stakeholder groups from universities, industry and medicine to discuss topics pertaining to new technologies, drug discovery, personalized medicine, and open science and innovation.
More information
News 21.06.2018 Zurich-Schlieren, June 21, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, announced today the appointment of Pamela A. Trail, Ph.D., as Chief Scientific Officer. Pamela Trail served most recently as Vice President of Oncology Strategy and Program Direction...
News 19.06.2018 Kuros Biosciences will this week present results from several investigator-led clinical case studies of MagnetOs Granules at the 15thannual State of Spine Surgery Think Tank, a leading conference uniquely dedicated to innovation in spinal surgery. The case studies, in which MagnetOs Granules were implanted in the spine, were performed by Alwyn...
News 15.06.2018 Zurich-Schlieren, June 15, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, announced today that the company will present updated preliminary results from the ongoing Phase 2 study of its lead proprietary oncology drug MP0250 at the 23th Annual...